Capital World Investors Incyte Corp Transaction History

Capital World Investors

$625 Billion
Q3 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$68.67 - $84.02 $1,030 - $1,260	-15 Reduced -0.0%	396,000 $27.2 Million
Q2 2021 Aug 16, 2021	BUY	$79.87 - $87.53 $1,198 - $1,312	15 Added 0.0%	396,015 $33.3 Million
Q3 2020 Nov 13, 2020	SELL	$85.07 - $109.69 $12.9 Million - $16.7 Million	-151,796 Reduced 27.71%	396,000 $35.5 Million
Q2 2020 Aug 14, 2020	SELL	$74.18 - $108.93 $321,347 - $471,884	-4,332 Reduced 0.78%	547,796 $57 Million
Q1 2020 May 15, 2020	SELL	$63.18 - $85.97 $10.5 Million - $14.3 Million	-165,894 Reduced 23.1%	552,128 $40.4 Million
Q4 2019 Feb 18, 2020	BUY	$73.04 - $95.72 $63,252 - $82,893	866 Added 0.12%	718,022 $62.7 Million
Q3 2019 Nov 14, 2019	BUY	$72.82 - $86.52 $51,920 - $61,688	713 Added 0.1%	717,156 $53.2 Million
Q2 2019 Aug 14, 2019	SELL	$73.52 - $88.7 $3,234 - $3,902	-44 Reduced 0.01%	716,443 $60.9 Million
Q1 2019 May 15, 2019	BUY	$63.56 - $88.17 $88,920 - $123,349	1,399 Added 0.2%	716,487 $61.6 Million
Q4 2018 Feb 14, 2019	SELL	$58.5 - $69.94 $18,544 - $22,170	-317 Reduced 0.04%	715,088 $45.5 Million
Q3 2018 Nov 14, 2018	SELL	$61.75 - $74.23 $15.1 Million - $18.1 Million	-243,998 Reduced 25.43%	715,405 $49.4 Million
Q2 2018 Aug 14, 2018	SELL	$60.85 - $83.98 $250 Million - $346 Million	-4,114,197 Reduced 81.09%	959,403 $64.3 Million
Q1 2018 May 15, 2018	SELL	$83.06 - $100.98 $86.7 Million - $105 Million	-1,043,824 Reduced 17.06%	5,073,600 $423 Million
Q4 2017 Feb 14, 2018	SELL	$93.56 - $116.6 $54.8 Million - $68.3 Million	-585,693 Reduced 8.74%	6,117,424 $579 Million
Q3 2017 Nov 14, 2017	BUY	$109.15 - $138.27 $732 Million - $927 Million	6,703,117	6,703,117 $783 Million

Others Institutions Holding INCY

# of Institutions

644

Shares Held

186M

Call Options Held

714K

Put Options Held

557K

View Full List

About INCYTE CORP

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16.8B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

More about INCY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital World Investors, based on Form 13F filings with the SEC.

News

Stay updated on Capital World Investors with notifications on news.

Account